Cadrenal Therapeutics, Inc.
CVKD
$1.19
-$0.01-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.82% | -22.72% | -12.49% | 22.09% | 119.10% |
| Depreciation & Amortization | 25.00% | -89.09% | 50.00% | 0.00% | -20.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.55% | -35.99% | -28.36% | 11.13% | 51.39% |
| Operating Income | 10.55% | 35.99% | 28.36% | -11.13% | -51.39% |
| Income Before Tax | 9.40% | 35.08% | 27.42% | -11.54% | -53.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.40% | 35.08% | 27.42% | -11.54% | -53.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.40% | 35.08% | 27.42% | -11.54% | -53.25% |
| EBIT | 10.55% | 35.99% | 28.36% | -11.13% | -51.39% |
| EBITDA | 10.55% | 35.91% | 28.36% | -11.13% | -51.41% |
| EPS Basic | 38.99% | 50.28% | 59.86% | 39.76% | 16.62% |
| Normalized Basic EPS | 38.99% | 50.27% | 59.86% | 39.75% | 16.63% |
| EPS Diluted | 38.99% | 50.28% | 59.86% | 39.76% | 16.62% |
| Normalized Diluted EPS | 38.99% | 50.27% | 59.86% | 39.75% | 16.63% |
| Average Basic Shares Outstanding | 48.51% | 30.56% | 80.80% | 85.14% | 83.81% |
| Average Diluted Shares Outstanding | 48.51% | 30.56% | 80.80% | 85.14% | 83.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |